Healthcare provider profile · identity verified

Ashley Pritchett Simms, NP-C

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CARTERSVILLE, GA · NPI 1932610185

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Ashley Pritchett Simms, NP-C received $49.84 in general payments during 2025 across 2 reported records.

Genentech USA, Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$49.84

2 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Genentech USA, Inc. Unresolved — no canonical attribution shown $49.84100.0%22025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$49.842

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Tecentriq
Normalized: tecentriq
Biological Genentech USA, Inc. $49.84 2 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium18160
LisinoprilLisinopril11649
OmeprazoleOmeprazole11642
Amlodipine BesylateAmlodipine Besylate11237
Levothyroxine SodiumLevothyroxine Sodium10935
Trazodone HclTrazodone Hcl8324
Metformin HclMetformin Hcl7624
Albuterol Sulfate HfaAlbuterol Sulfate7041
Pantoprazole SodiumPantoprazole Sodium6822
GabapentinGabapentin6216
Losartan PotassiumLosartan Potassium6224
Fluoxetine HclFluoxetine Hcl5715
HydrochlorothiazideHydrochlorothiazide5719
Sertraline HclSertraline Hcl5620
SimvastatinSimvastatin5617
Alendronate SodiumAlendronate Sodium5319
MeloxicamMeloxicam4920
Metformin Hcl ErMetformin Hcl4818
Escitalopram OxalateEscitalopram Oxalate4715
FamotidineFamotidine4717
Tizanidine HclTizanidine Hcl4511
GlimepirideGlimepiride44suppressed
Metoprolol SuccinateMetoprolol Succinate4416
Buspirone HclBuspirone Hcl4315
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide4214
MupirocinMupirocin4226
Doxycycline HyclateDoxycycline Hyclate4030
FurosemideFurosemide4015
Zolpidem TartrateZolpidem Tartrate39suppressed
Rosuvastatin CalciumRosuvastatin Calcium3814
Fluticasone PropionateFluticasone Propionate3712
Citalopram HbrCitalopram Hydrobromide3512
Pravastatin SodiumPravastatin Sodium3511
Ciprofloxacin HclCiprofloxacin Hcl3429
AlprazolamAlprazolam32suppressed
Tamsulosin HclTamsulosin Hcl3113
AllopurinolAllopurinol30suppressed
EliquisApixaban28suppressed
OzempicSemaglutide28suppressed
Ropinirole HclRopinirole Hcl28suppressed
MethylprednisoloneMethylprednisolone2727
Montelukast SodiumMontelukast Sodium27suppressed
Potassium ChloridePotassium Chloride26suppressed
Metoprolol TartrateMetoprolol Tartrate2512
Tramadol HclTramadol Hcl2317
Diclofenac SodiumDiclofenac Sodium22suppressed
GlipizideGlipizide22suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21suppressed
MounjaroTirzepatide21suppressed
RybelsusSemaglutide20suppressed
FluconazoleFluconazole1916
Venlafaxine Hcl ErVenlafaxine Hcl19suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav1818
ClopidogrelClopidogrel Bisulfate18suppressed
CarvedilolCarvedilol17suppressed
Incruse ElliptaUmeclidinium Bromide17suppressed
AmoxicillinAmoxicillin1612
AtenololAtenolol16suppressed
Azelastine HclAzelastine Hcl16suppressed
Bupropion XlBupropion Hcl16suppressed
CelecoxibCelecoxib16suppressed
Cyclobenzaprine HclCyclobenzaprine Hcl1611
Ondansetron OdtOndansetron1613
AzithromycinAzithromycin1514
Donepezil HclDonepezil Hcl15suppressed
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim1514
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14suppressed
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide14suppressed
NystatinNystatin14suppressed
Paroxetine HclParoxetine Hcl14suppressed
PrednisonePrednisone1414
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid14suppressed
ValacyclovirValacyclovir Hcl14suppressed
Bupropion Hcl SrBupropion Hcl13suppressed
Esomeprazole MagnesiumEsomeprazole Magnesium13suppressed
Oxybutynin ChlorideOxybutynin Chloride13suppressed
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13suppressed
CefdinirCefdinir1212
Folic AcidFolic Acid12suppressed
Hydroxyzine HclHydroxyzine Hcl12suppressed
Meclizine HclMeclizine Hcl12suppressed
Triamcinolone AcetonideTriamcinolone Acetonide12suppressed
ValsartanValsartan12suppressed
Amitriptyline HclAmitriptyline Hcl11suppressed
BaclofenBaclofen11suppressed
Duloxetine HclDuloxetine Hcl11suppressed
EstradiolEstradiol11suppressed
Memantine HclMemantine Hcl11suppressed
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11suppressed
Quetiapine FumarateQuetiapine Fumarate11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $49.84 · 2 records Genentech USA, Inc. Tecentriq
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error